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Background/Aims: Estrogen is known to have protective effect in colorectal can-
cer development. The aims of this study are to investigate whether estradiol treat-
ment reduces inflammation in CCD841CoN, a female human colonic epithelial 
cell line and to uncover underlying mechanisms of estradiol effects.
Methods: 17β-Estradiol (E2) effect was measured by Western blot after inducing 
inf lammation of CCD841CoN by tumor necrosis factor α (TNF-α). Expression 
levels of estrogen receptor α (ERα) and β (ERβ), cyclooxygenase-2 (COX-2), nuclear 
factor-κB (NF-κB), heme oxygenase-1 (HO-1), and NAD(P)H-quinone oxidoreduc-
tase-1 (NQO-1) were also evaluated.
Results: E2 treatment induced expression of ERβ but did not increase that of ERα. 
E2 treatment for 48 hours significantly elevated the expression of anti-oxidant 
enzymes, HO-1 and NQO-1. TNF-α treatment significantly increased the level of 
activated NF-κB (p < 0.05), and this increase was significantly suppressed by treat-
ment of 10 nM of E2 (p < 0.05). E2 treatment ameliorated TNF-α-induced COX-2 
expression and decrease of HO-1 expression. 4-(2-phenyl-5,7-bis(trifluoromethyl)
pyrazolo(1,5-a)pyrimidin-3-yl)phenol (PHTPP), antagonist of ERβ, removed the 
inhibitory effect of E2 in the TNF-α-induced COX-2 expression (p = 0.05).
Conclusions: Estrogen seems to inhibit inflammation in female human colonic 
epithelial cell lines, through down-regulation of NF-κB and COX-2 expression 
and induction of anti-oxidant enzymes such as HO-1 and NQO-1.
Keywords: Estrogens; Estrogen receptor beta; Inflammation; NF-kappa B; Heme 
oxygenase-1.
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INTRODUCTION
Colorectal cancer (CRC) development is closely related 
to cancer-related inflammation connected by various 
pathways such as nuclear factor-κB (NF-κB) signaling 
pathway [1]. Activation of NF-κB modulates produc-
tion of inflammatory mediators, importantly cyclooxy-
genase-2 (COX-2) [1]. It is widely accepted that COX-2 
has key roles in development of CRC [2,3]. For instance, 
COX-2 is overexpressed in most CRC tissue [4] and se-
lective inhibition of COX-2 using celecoxib results in 
prominent prevention of CRC [2]. 
Previously our team reported that colitis-associated 
colon tumorigenesis in azoxymethane/dextran sulfate 
sodium (AOM/DSS) model was induced more severely 
in male mice than female mice by way of inflammatory 
mediators such as interleukin 1β (IL-1β) and myeloper-
oxidase [5]. In addition, we found that 17β-estradiol (E2; 
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10 mg/kg) inhibited the initiation of CRC by upregulat-
ing nuclear factor erythroid 2-related factor 2 (NRF2), 
a transcriptional factor-related pathways in the AOM/
DSS-treated male Institute of Cancer Research mice [6]. 
Actually, NRF2 induces many genes including anti-oxi-
dant enzymes [7] in breast cancer cell line [8]. 
Estrogen, especially, biologically active metabolite E2 
has extensive roles in carcinogenesis of both reproduc-
tive organs (breast, ovary, and uterus) and non-repro-
ductive organs (lung, intestine) [9]. In contrast, many 
epidemiologic data suggest protective role of estrogen 
in CRC development [10-12]. These contradictory results 
could be related that estrogen has two types of recep-
tors, estrogen receptor α (ERα) and β (ERβ) encoded by 
different genes which have different expression patterns 
between tissues and organs [13]. Laboratory investigation 
shows ERβ is the predominant ER subtype in colon ade-
nocarcinoma cell lines [14]. For instance, in ERβ–/– mice, 
the differentiation states of colonic epithelial cells are 
different from that of wild type mice [15]. Furthermore 
ERβ is closely related to anti-inflammatory effects of 
estrogen. Microarray analysis suggests ERβ selective 
agonist repressing transcription of inflammatory genes 
such as tumor necrosis factor α (TNF-α) and IL-6 in hu-
man osteosarcoma cells [16], and estrogen suppressed 
COX-2 induction by regulating NF-κB in rat cerebral 
blood vessels [17]. 
Heme oxygenase-1 (HO-1) is a key anti-oxidant enzyme 
that has anti-inflammatory activity and pro-resolving ef-
fect [18]. HO-1 inducer treatment results in reduced co-
lonic inflammation and colonic epithelium of patients 
with inflammatory bowel disease shows dysregulation of 
HO-1 expression [19]. Regulation of HO-1 expression is 
related to estrogen that phytoestrogen having structural 
similarity with E2 upregulates HO-1 [20]. Actually HO-1 
has critical role in protective effect of E2 on shock-in-
duced intestinal injury [21]. We also found that pre-treat-
ment of estradiol increased mRNA expression of an-
ti-oxidant enzymes (i.e., HO-1, glutamate-cysteine ligase 
modifier subunit [GCLM], and NAD(P)H-quinone ox-
idoreductase-1 [NQO-1]) in AOM/DSS treated male mice, 
suggesting estrogen-NRF2-HO-1 pathway [6]. However, 
it is not direct experiment regarding estrogen-effect in 
the inflammation-induced colonic epithelial cells. 
Activation of NRF2 leads to the increased expression 
of HO-1, to inhibit the NF-κB signalling, which results 
in the mitigated intestinal mucosa injury and restored 
tight-junction dysfunction, in male rat liver transplan-
tation model [22]. Kelch-like ECH-assiciated protein-1 
(KEAP1), a negative regulator of NRF2, suppress the tran-
scriptional action of NRF2 under normal conditions [23]. 
From this background, we hypothesized that estro-
gen inhibits inflammation and induces antioxidant en-
zymes through transcriptional regulation by ERs. To as-
sess this hypothesis, we explored modulation of COX-2 
and anti-oxygen enzyme expression which was induced 




The CCD841CoN cells (colonic epithelial cell line orig-
inated from female fetus) were kindly provided by Lab-
oratory of Professor Y.J.S. (Tumor Microenvironment 
Global Core Research Center, Seoul National Universi-
ty College of Pharmacy, Seoul, Korea) and maintained 
in Minimum Essential Media supplemented with 10% 
fetal bovine serum (FBS) and antibiotic-antimycot-
ic mixture (Gibco BRL, Gaithersburg, MD, USA). The 
cells kept in 10% charcoal-stripped FBS (CSS) for 24 
hours were treated with or without 10 ng/mL human 
recombinant TNF-α for 6 hours (210-TA-005, R&D sys-
tem, Minneapolis, MI, USA) in the absence or presence 
of 1, 10, 100 nM water soluble E2 (Sigma E4389, Sig-
ma-Aldrich Co., St. Louis, MO, USA) for 24 or 48 hours. 
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)py-
rimidin-3-yl)phenol (PHTPP), an antagonist of ERβ, was 
treated. All cells were cultured at 37°C in a 95% humidi-
fied atmosphere containing 5% CO2.
Western blot analysis
After treatment, the media in the apical side was aspirat-
ed and the cells were collected by centrifugation at 1,000 
rpm for 5 minutes at 4°C. Cells were suspended in the 
RIPA cell lysis buffer (Cell Signaling Technology, Bever-
ly, MA, USA) with protease and phosphatase inhibitors 
and kept on ice for 20 minutes. After centrifugation at 
13,000 rpm for 15 minutes, the supernatant was collected 
and stored at –70°C until use.
Whole cell extracts were isolated using RIPA buffer 
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with protease and phosphatase inhibitors. Cytoplasmic 
and nuclear lysates were separated using a NE-PER Nu-
clear Cytoplasmic Extraction Reagent kit (Pierce, Rock-
ford, IL, USA) according to the manufacturer’s instruc-
tions. Protein concentration was determined using the 
bicinchoninic acid (BCA) protein assay reagent (Pierce). 
Protein samples were mixed with an equal volume of 5 × 
sodium dodecyl sulfate (SDS) sample buffer, boiled for 5 
minutes, and then separated using 8% to 15% SDS-poly-
acrylamide gel electrophoresis (PAGE). After electropho-
resis, proteins were transferred to polyvinylidene difluo-
ride (PVDF) membranes. The membranes were blocked 
with 5% nonfat dry milk in Tris-buffered saline with 
Tween-20 buffer (TBS-T) for 1 hour at room tempera-
ture. Membranes were incubated overnight at 4°C with 
specific antibodies. Primary antibodies were removed 
by washing the membranes three times in TBS-T, and 
incubated for 2 hours with horseradish peroxidase-con-
jugated anti-rabbit, anti-goat, or anti-mouse immuno-
globulin (Santa Cruz Biotechnology, Dallas, TX, USA). 
Following three washes with TBS-T, antigen-antibody 
complexes were detected using the SuperSignal West 
Pico Chemiluminescence System (Thermo Fisher Sci-
entific, Rockford, IL, USA). The antibodies are listed in 
detail in the Table 1.
Quantitative real-time polymerase chain reaction 
The CCD841CoN cells kept in 10% CSS for 24 hours 
were treated with or without 10 ng/mL human recom-
binant TNF-α for 6 hours in the absence or presence of 
10 nM E2 for 48 hours. Total RNA was prepared from 
the cells using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instruments, and 
quantified using a NanoDrop ND-1000 device (Thermo 
Scientific, Wilmington, DE, USA). Complementary DNA 
(cDNA) was synthesized using the High Capacity cDNA 
reverse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA). The cDNA was used to perform quan-
titative real-time polymerase chain reaction (qRT-PCR) 
using specific primers (listed in Table 2) and Power 
SYBR Green PCR Master mix (Thermo Fisher Scientific, 
Waltham, MA, USA) in Viia7 instrument (Applied Bio-
systems). Expression levels of the genes were normalized 
to that of glyceraldehyde 3-phosphate dehydrogenase.
Statistical analyses
Data are expressed as mean ± SEM. Statistical signifi-
cance was examined with Mann-Whitney test or Fisher’s 
exact test. A p < 0.05 was considered to indicate a statis-
tical significance. All statistical analyses were conducted 
using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) 
and GraphPad Prism software (GraphPad, La Jolla, CA, 
USA).
RESULTS
E2 treatment increases ERβ expression and induces 
anti-oxidant enzymes in colonic epithelial cells
First of all ER expression patterns were investigated in 
CCD841CoN depending on E2 treatment time (24-, 48-
hour) and concentration (1, 10, 100 nM) using Western 
Table 1. List of antibodies and its characteristic 
Antigen Antibody Experimental conditions
COX-2 Santa Cruz Biotechnology (sc1745) WB (1:1,000)
NF-κB p65 Santa Cruz Biotechnology (sc8008) WB (1:1,000)
HO-1 Abcam (ab13248) WB (1:1,000)
NQO1 Abcam (ab34173) WB (1:5,000)
ERα Abcam (ab93021) WB (1:1,000)
ERβ Abcam (ab3576) WB (1:1,000)
β-Actin Santa Cruz Biotechnology (sc47778) WB (1:4,000)
Lamin B Santa Cruz Biotechnology (sc6216) WB (1:4,000)
COX-2, cyclooxygenase-1; WB, Western blot; NF-κB, nuclear factor-κB; HO-1, heme oxygenase-1; NQO-1, NAD(P)H-quinone 
oxidoreductase-1; ERα, estrogen receptor α; ERβ, estrogen receptor β.
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blot analysis. ERα expression has no significant change 
after E2 treatment (Fig. 1A). In contrast 48 hours of E2 
treatment consistently increased ERβ expression from 1 
nM concentration of E2 (p < 0.05) (Fig. 1B). 
In the next anti-oxidant enzyme expressions were 
measured following E2 treatment by Western blot anal-
ysis. Low basal level expression of HO-1 showed con-
centration-dependent increment of expression after 48 
hours E2 treatment (p < 0.05) (Fig. 1C). NQO-1, another 
antioxidant enzyme, also increased after 48 hours E2 
treatment although it is not prominent as HO-1 due to 
high basal level expression (p < 0.05) (Fig. 1D). Strangely 
the expression of NQO-1 decreased by 24 hours incuba-
tion of E2 (p < 0.05) (Fig. 1D).
Forty-eight hours E2 treatment with 10 nM concen-
tration showed the most stable expression of ERβ and 
antioxidant enzymes, HO-1 and NQO-1 (Fig. 1E). There-
fore, we further performed experiment with 48 hours of 
10 nM E2 treatment.
E2 treatment inhibits NF-κB pathway and increases 
HO-1 expression following TNF-α induced inflam-
mation
To mimic inflammatory environment colonic epitheli-
al cells were treated with TNF-α (10 ng/mL) for 6 hours 
just after 18-hour treatment of E2 (Fig. 2A). ERβ expres-
sion level increased when both 10 nM E2 and 10 ng/mL 
TNF-α were administrated while TNF-α treatment alone 
did not show any significant change of ERβ expression 
(Fig. 2B). Next, we measured severity of inflammation by 
NF-κB and COX-2 expression levels. TNF-α treatment 
for 10 to 20 minutes significantly increased the level of 
activated NF-κB (p < 0.05), and this increase was signifi-
cantly suppressed in the cells by treatment of 10 nM of 
E2 (p < 0.05). In contrast, 10 ng/mL TNF-α treatment in-
duced high level of COX-2 expression (p < 0.001) while 
E2 treatment attenuated the increased level of COX-2 
(p < 0.05) (Fig. 2D). HO-1, a representative antioxidant 
enzyme, decreased its expression by 10 ng/mL TNF-α 
treatment (p < 0.05). However, the pretreatment of 10 nM 
E2 prevented TNF-α–induced decrease of HO-1 expres-
sion (p < 0.01) (Fig. 2E). Furthermore pretreatment of 10 
nM E2 further increased HO-1 level similar to that of 
10 nM E2 treatment alone, which was very higher than 
the control (p < 0.001) (Fig. 2E). As shown in Fig. 2F, the 
protein expression of COX-2 was significantly increased 
with TNF-α (p < 0.05). Again this increase was inhibited 
by E2 (p = 0.05), and the effect of E2 vanished by PHTPP 
(p = 0.05).
The mRNA expression of HO-1 was significantly de-
creased with either TNF-α or E2 (p < 0.05) (Fig. 2G). The 
increase of HO-1 mRNA expression by E2 was not sta-
tistically significant (p > 0.05). Similarly, the mRNA ex-
pression of NQO-1 was significantly reduced with either 
TNF-α or E2 (p < 0.05) (Fig. 2H). However, E2 did not 
significantly recover the level of NQO-1 mRNA level (p 
> 0.05).
Influence of E2 on the TNF-α-induced expression of 
KEAP1 and NRF2
The protein expression level of KEAP1 showed no sig-
nificant difference according to the treatment of TNF-α 
and E2 (Fig. 3A). The protein expression level of NRF2 
seemed to increase when the 10 ng/mL TNF-α was treat-
ed for 6 hours. E2 the NRF2 protein expression when it 
was treated for 2 to 3 hours. At 6 hours, the NRF2 protein 
level decreased with E2.
After treatment of TNF-α and/or E2 for 6 hours, the 
mRNA expression of KEAP1 was significantly dimin-
ished by either TNF-α or E2, respectively (p < 0.05) (Fig. 
3B). However, the increase of KEAP1 mRNA level by E2 
was not statistically significant (p > 0.05). The mRNA 
expression of NRF2 was significantly increased with 
Table 2. List of oligonucleotides for quantitative real-time 
polymerase chain reaction 
Gene Sequence (5’→3’)
HO-1 F: ATG GCC TCC CTG TAC CAC ATC
R: TGT TGC GCT CAA TCT CCT CCT
NQO-1 F: CGC AGA CCT TGT GAT ATT CCA G
R: CGT TTC TTC CAT CCT TCC AGG
NRF2 F: TGC CCC TGG AAG TGT CAA ACA
R: CAA CAG GGA GGT TAA TGA TTT
KEAP1 F: CAG ATT GGC TGT GTG GAG TT
R: GCT GTT CGC AGT CGT ACT TG
GAPDH F: TTC ACC ACC ATG GAG AAG GC
R: GGC ATG GAC TGT GGT CAT GA
HO-1, heme oxygenase-1; NQO-1, NAD(P)H-quinone ox-
idoreductase-1; NRF2, nuclear factor erythroid 2-related fac-
tor 2; KEAP1, Kelch-like ECH-associated protein 1; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase.
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Figure 1. 17β-Estradiol (E2) treatment increases estrogen re-
ceptor β (ERβ) expression and induces anti-oxidant enzymes 
in colonic epithelial cells. E2 in various concentrations (1, 
10, 100 nM) and hours (24, 48 hours) did not show difference 
in estrogen receptor α (ERα) expression measure by Western 
blot analysis (A) while ERβ increases its expression when 1, 
10, or 100 nM of E2 was treated for 48 hours (B). (C) Heme 
oxygenase-1 (HO-1) has concentration-dependent increment 
of expression after 48 hours of E2 treatment. (D) NAD(P)
H-quinone oxidoreductase-1 (NQO-1) also increases after 48 
hours of E2 treatment. (E) Comparison between ERs and an-
tioxidant enzymes, HO-1 and NQO1 expression level treated 
with 10 nM of E2 for 48 hours. CSS, charcoal-stripped fetal 
bovine serum; NS, not significant. ap < 0.05 compared with 
the control (0, white bar) of target gene expression, bp < 0.05 
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Figure 2. 17β-Estradiol (E2) treatment inhibits nuclear factor-κB (NF-κB) pathway and increases heme oxygenase-1 (HO-1) 
expression following tumor necrosis factor α (TNF-α) induced inflammation. (A) Scheme for experimental courses to evalu-
ate effects of E2 when TNF-α induces inflammation. (B) Estrogen receptor β (ERβ) expression level analyzed by Western blot 
analysis increases when both E2 and TNF-α are administrated. (C) The time-dependent protein expression level of NF-κB 
during the treatment of TNF-α and TNF-α + E2 for 360 minutes. (D) TNF-α treatment induces high level of cyclooxygenase-2 
(COX-2) expression and E2 treatment does not show significant difference of the level. (E) HO-1 increases its expression when 
both E2 and TNF-α were administered compared to the group only TNF-α was treated. (F) An antagonist of ERβ, 4-(2-phe-
nyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol (PHTPP), removed the inhibitory effect of E2 in the TNF-α-
induced increase of COX-2 expression. (G, H) The mRNA expression of antioxidants (HO-1 and NQO-1). NS, not significant. ap 
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TNF-α (p < 0.05), and it was reduced by E2 (p < 0.05) (Fig. 
3C).
DISCUSSION
As demonstrated in our previous report, sex differenc-
es occur in CRC development by showing lower tumor 
multiplicity and lower incidence in AOM/DSS-treated 
female mice compared with AOM/DSS-treated male 
mice [5]. When we further investigated the underlying 
anti-cancer mechanism of estrogen it suggested im-
portant roles of NF-κB inflammatory signaling pathway 
and anti-oxidant enzymes in cancer-related inflamma-
tion and carcinogenesis in vivo system [6]. However, the 
results were rather complicated mainly because in vivo 
animal reflects multi-signal condition system [6]. The 
cell line in vivo system might be more clear and straight 
forward to reveal sex-specific medicine in CRC. Recent-
ly, National Institutes of Health (NIH) announced that 
grant applicants must consider the sex of animals and 
cells in study design, and it is being encouraged to mon-
itor sex of cells in preclinical studies [24]. Therefore, in 
the present study, we used female human cell lines, 
reflecting the recent encourage about considering sex 
differences in cell line experiments. The present study 
shows that E2 treatment reduces COX-2 expression and 
increases the anti-oxidant enzyme, i.e., HO-1 expression 
possibly mediated by ERβ, which have not been shown 
in previous studies to our knowledge.
The NF-κB signaling pathway is very involved in in-
flammation and cancer development, especially in 
CSS medium
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Figure 3. The expression levels of Kelch-like ECH-assiciated protein-1 (KEAP1) and nuclear factor erythroid 2-related factor 2 
(NRF2) in colonic epithelial cell lines, treated with tumor necrosis factor α (TNF-α) and/or 17β-estradiol (E2). (A) Protein ex-
pression level of KEAP1 and NRF2, during 0 to 6 hours of treatment. The mRNA expression levels of KEAP1 (B) and NRF2 (C) 
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colitis-associated CRC [25]. In the present study, E2 
treatment inhibited COX-2 expression as well as NF-
κB activation during TNF-α-induced inflammation in 
the colonic epithelial cell line. However, inhibition of 
NF-κB by E2 appeared only in the early period of E2 
treatment (Fig. 2C). This consistent response to E2 treat-
ment of both NF-κB and COX-2 suggests that E2 might 
control COX-2 through inhibition of NF-κB. However, 
tissue-specific modulation of COX-2 expression in the 
uterus and the vena cava by estrogen showed compli-
cated nature of COX-2 modulation [26]. In addition, 
there was a report in colorectal cell lines, which showed 
positive and negative regulation of NF-κB by COX-2 by 
different prostaglandins [27]. Thus more experiments 
are needed for clarification of this relationship between 
NF-κB and COX-2 in terms of estrogen. The inhibitory 
effect of E2 on COX-2 expression is further evidenced by 
the increase of COX-2 expression in the colonic cell line 
treated with TNF-α, and disappearance of E2-induced 
decrease effect by PHTPP, an antagonist of ERβ.
It has been reported that anti-oxidant enzymes acti-
vated by NRF2 have cancer preventive effects by elimi-
nating reactive oxygen species [28] and facilitating the 
resolution of inflammation [18]. In the present study, 
the levels of HO-1 expression were different between 
control and E2 treated cells, implicating the NRF2-re-
lated anti-oxidant reaction as an underlying mecha-
nism of the protective effect of estrogen. These results 
are in accordance with the increased susceptibility to 
DSS-induced colitis and colitis-associated colon cancer 
in NRF2 knockout mice [29,30]. We clearly showed that 
prevention of TNF-α-induced decrease of HO-1 expres-
sion by E2 pretreatment (p < 0.01), and E2 furthermore 
increased the level of HO-1 expression similar to that of 
10 nM E2 treatment alone, which was very higher than 
the control (p < 0.001). It means that E2 stimulation of 
HO-1 becomes very strong when the cell line is attacked 
by inflammatory condition by such as TNF-α. Probably 
it is related with characteristics of CCD841CoN originat-
ed from female fetus. There has been interesting report 
that 11-oxidoreductase activity and basal and cortisone- 
or cortisol-stimulated fibroblast-pneumonocyte factor 
activity has been significantly higher in the female than 
male fibroblast cell line which has been established 
from 19 days’ gestation rat fetal lung [31]. These differ-
ences would lead to a sex difference in the synthesis of 
pulmonary surfactant [31]. In addition, it was reported 
that gender dissimilarity appears in radiosensitivity as 
measured in 152 fibroblast cell cultures obtained from 
normal individuals [32]. Thus it would be interesting if 
comparison experiment is performed in male originat-
ed colon cancer cell line in addition to female originat-
ed cell line, CCD841CoN. Actually this is the limitation 
of our study. Furthermore, we could not get consistent 
expression results between mRNA and protein of an-
ti-oxidant enzymes such as HO-1 and NQO1. According 
to previous report, the expression correlation between 
mRNA and protein can be as little as 40% depending 
on the system, and there are many processes between 
transcription and translation [33]. Actually, we focused 
on the time that the E2 treatment regulated the protein 
expressions on CCD841CoN cells. To investigate the ex-
pression correlation, it is necessary to perform further 
mechanistic studies on E2 treatment time series.
KEAP1/NRF2 signalling pathway regulates anti-in-
flammatory gene expression to suppress the progres-
sion of inflammation [22]. The upregulation of NRF2 
by E2 during 2 to 3 hours after treatment is consistent 
with a previous study that reported the stimulation of 
NRF2-KEAP1 antioxidant defense in human neuroblast 
cell line [34]. The persistent expression of KEAP1 with 
little variation during TNF-α/E2 treatment was in accor-
dance with previous results [35]. According to the mRNA 
and protein expression levels of NRF2 (Fig. 3A and 3C), 
E2 might promote the expression of NRF2 during 2 to 
3 hours after treatment, and then inhibit the NRF2 ex-
pression at 6 hours, in CCD841CoN. 
In conclusion, estrogen seems to inhibit inflammation 
in female human colonic epithelial cell lines, through 
down-regulation of NF-κB and COX-2 expression and 
induction of anti-oxidant enzymes such as HO-1 and 
NQO-1.
KEY MESSAGE
1. In colonic epithelial cell line originated from fe-
male fetus, 17β-estradiol (E2) treatment induced 
expression of estrogen receptor β, increased the 
expression of anti-oxidant enzymes including 
heme oxygenase-1 (HO-1) and NAD(P)H-qui-
none oxidoreductase-1. After tumor necrosis 
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